Skip to main content

Smoke-free law linked to large fall in hospital admissions for childhood asthma

Research led by Dr Chris Millett from the Department of Primary Care and Public Health at Imperial College London reported that the introduction of smoke-free legislation in England was immediately followed by a fall in the number of children admitted to hospital with asthma symptoms, a new study has found.

NHS statistics analysed Dr Millett and his colleagues show a 12.3 per cent fall in admissions for childhood asthma in the first year after the law on smoking in enclosed public places and workplaces came into effect in July 2007. Asthma admissions continued to fall in subsequent years, suggesting that the benefits of the legislation were sustained over time. The effect was equivalent to 6,802 fewer hospital admissions in the first three years of the legislation, in the analysis published in the US journal Pediatrics.

Dr Millett said: "There is already evidence that eliminating smoking from public places has resulted in substantial population health benefits in England, and this study shows that those benefits extend to reducing hospital admissions for childhood asthma. Previous studies have also suggested that the smoke-free law changed people's attitudes about exposing others to second-hand smoke and led more people to abstain from smoking voluntarily at home and in cars. We think that exposing children to less second-hand smoke in these settings probably played in important role in reducing asthma attacks. The findings are good news for England, and they should encourage countries where public smoking is permitted to consider introducing similar legislation."

The study was widely reported in the media including by the BBC, Guardian and Telegraph.

Comments

Popular posts from this blog

MPH Student Presentations on the NHS Care.Data Programme

As part of a session on primary care data in the Health Informatics module on the Imperial Master of Public Health Programme, I asked students to work in two groups to present arguments for and against the NHS Care.Data programme. Care.Data is an NHS programme that will extract data from the medical records held by general practitioners (GPs) in England. The Care.Data programme takes advantage of the very high level of use of electronic medical records by GPs in England. After extraction, data will be uploaded to the NHS Health and Social Care Information Centre (HSCIC). The data will then be used for functions such as health care planning, monitoring disease patterns and research. The programme has been controversial with proponents arguing that the programme will bring many benefits for the NHS and the population of England; and opponents arguing it is a major breach of privacy. You can view the two presentations to help inform you further about these arguments: Arguments fo...

What is the difference between primordial prevention and primary prevention?

Primordial prevention and primary prevention are both crucial strategies for promoting health, but they operate at different levels. Primordial prevention aims to address the root causes of health problems and improve the wider determinants of health. It focuses on preventing the emergence of risk factors in the first place by tackling the underlying social, economic, and environmental determinants of health. This involves broad, population-wide interventions such as: Policies that promote healthy food choices: Think about initiatives like taxing sugary drinks to discourage unhealthy consumption, or providing subsidies for fruits and vegetables to make them more accessible. Urban planning that prioritises well-being: This could include creating walkable neighborhoods with safe cycling routes, ensuring access to green spaces for recreation and relaxation, and designing communities that foster social connections. Social programs that address inequality: Initiatives aimed at reducing pov...

Talking to Patients About Weight-Loss Drugs

The use of weight-loss drugs such as GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) has increased rapidly in recent years. These drugs can help some people achieve significant weight reduction, but they are not suitable for everyone and require careful counselling before starting treatment. By discussing benefits, risks, practicalities, and  uncertainties, clinicians can help patients make informed, realistic decisions about their treatment. Key points to discuss with patients 1. Indications and eligibility These drugs are usually licensed for adults with a specific BMI. They should be used alongside lifestyle interventions such as dietary change, increased physical activity, and behaviour modification. 2. Potential side effects – some can be serious Common adverse effects include nausea, vomiting, diarrhoea, and abdominal discomfort. Less common but more serious risks include gallstones, pancreatitis and visual problems. Patients should know what to watch for a...